Waters and Labcorp to widen access to cervical cancer screening with HPV test

what happened

Waters Corp. and Labcorp have agreed to expand access to cervical cancer screening. According to Reuters, from late 2026 the BD Onclarity HPV Assay, which the companies describe as the most comprehensive FDA-approved HPV testing option, will be available through Labcorp's laboratory network.

As TradingView reports, citing dpa-AFX, Labcorp intends to become the first commercial laboratory to offer the test for both clinician-collected and self-collected samples, in clinics, patient service centers and at home. The test supports ASCCP risk-based management guidelines and provides extended HPV genotyping. Labcorp will use it in its clinician programs, health-plan initiatives and the Labcorp OnDemand consumer channel.

Waters shares were flat at $455.59 after the bell, after closing the regular session down 0.41%.

why it matters

For markets this is a routine commercial update: the deal widens the sales channels for Waters' diagnostic test and Labcorp's reach in screening. No revenue figures or deal value were disclosed, and the small share reaction limits any impact on the stocks.

tags

instruments